- The Octopus Value Investing
- Posts
- Novo Nordisk A/S - 2024 Earnings Review
Novo Nordisk A/S - 2024 Earnings Review
Hope for Recovery After a Challenging Semester: Overcoming 'Everything That Went Wrong
The Octopus Value Investing
February 09, 2025
Following the annual reporting season, I am sharing Novo Nordisk 2024 earnings review in today’s newsletter after they reported earnings back on Wednesday 2024.02.05.
The reported results have been welcomed by the market, resulting in a share price increase of ↑3.9% at the end of the trading day. Let’s start!
DISCLAIMER: This article is not a recommendation to buy or sell any financial instrument, the content is educational and my personal opinion. Each person has to make his own analysis. Any action or decision you take as a result of viewing this article is your sole responsibility.
Reply